Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608765 | 0.86 | LMNA (0.49) | KDM4ELMNAMAPTALOX12L3MBTL1 | |
| SCHEMBL23832886 | 0.83 | HTT (0.46) | KDM4EMAPTPTGDR2ARHTT | |
| SCHEMBL317372 | 0.79 | KDM4E (0.49) | KDM4ELMNAMAPTTP53ALOX12 | |
| SCHEMBL3156281 | 0.79 | PSMD14 (0.56) | TSHRL3MBTL1PTGDR2ARHTT | |
| SCHEMBL667933 | 0.79 | HTT (0.42) | KDM4EMAPTTP53PTGDR2AR | |
| SCHEMBL10008410 | 0.79 | NR4A2 (0.56) | TSHRPTGDR2ARHTTLRRK2 | |
| SCHEMBL28906978 | 0.79 | KDM4E (0.54) | KDM4ELMNAMAPTTP53TSHR | |
| SCHEMBL7641703 | 0.77 | KDM4E (0.62) | KDM4EL3MBTL1KDM4ARAB9AEGLN1 | |
| SCHEMBL30668494 | 0.77 | KDM4E (0.66) | KDM4ELMNAMAPTTP53TSHR | |
| SCHEMBL1333120 | 0.77 | KDM4E (0.66) | KDM4ELMNAMAPTTP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119899214-A | Iridium-containing Lewis base catalyst and preparation method and application thereof | 山东汇盟生物科技股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| EP-4055014-B1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORP (KR) | 2025-04-30 | — | — | EP | disclosed |
| CN-119899214-A | Iridium-containing Lewis base catalyst and preparation method and application thereof | 山东汇盟生物科技股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-119798315-A | Preparation method of L-smart glufosinate | 山东汇盟生物科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-114867719-B | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2024-06-25 | — | — | CN | disclosed |
| US-11655235-B2 | Pyrrolidine and piperidine compounds | YUHAN CORPORATION (KR) | 2023-05-23 | — | — | US | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| CN-114867719-A | Pyrrolidine and piperidine compounds | 柳韩洋行 | 2022-08-05 | — | — | CN | disclosed |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | YUHAN CORPORATION (KR) | 2021-05-20 | — | — | US | disclosed |
| CN-101541751-A | Quinoline compounds | WYETH CORP (US) | 2009-09-23 | — | — | CN | disclosed |
| EP-2074098-A2 | QUINOLINE COMPOUNDS | Wyeth (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008049047-A2 | QUINOLINE COMPOUNDS | WYETH (US) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655235-B2 | Pyrrolidine and piperidine compounds | FAP, APC, VHL | KDM4E 1644/4885LMNA 1955/4885MAPT 1909/4885 |
| US-20210147386-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | FAP, APC, VHL | KDM4E 1644/4885LMNA 1955/4885MAPT 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.